

## Lutikizumab

Cat. No.:	HY-P99721
CAS No.:	1791411-57-8
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Lutikizumab (ABT-981) is an anti-IL-1 $\alpha$ and IL-1 $\beta$ dual variable domain immunoglobulin. Lutikizumab binds and inhibits IL-1 $\alpha$ and IL-1 $\beta$ . Lutikizumab can be used for the research of osteoarthritis <sup>[1]</sup> .								
<b>In Vitro</b>	ABT-981 shows simultaneously binding efficacy human IL- $\alpha$ and IL-1 $\beta$ molecules <sup>[1]</sup> . ABT-981 shows highly specific binding effects to IL- $\alpha$ and IL-1 $\beta$ over other IL-1 family members <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
<b>In Vivo</b>	Lutikizumab (0.0001-1 mg/kg, i.p., once) shows effective inhibition to the IL-6 production induced by IL-1 $\alpha$ and IL-1 $\beta$ <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Female C57/BL6 mice with IL-1<math>\alpha</math> and IL-1<math>\beta</math> injection<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>0.0001-1 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection, 0.0001-1 mg/kg, once</td> </tr> <tr> <td>Result:</td> <td>Dose-dependently decreased the murine IL-6 generated by human and cynomolgus IL-1<math>\alpha</math> and IL-1<math>\beta</math>.</td> </tr> </table>	Animal Model:	Female C57/BL6 mice with IL-1 $\alpha$ and IL-1 $\beta$ injection <sup>[1]</sup>	Dosage:	0.0001-1 mg/kg	Administration:	Intraperitoneal injection, 0.0001-1 mg/kg, once	Result:	Dose-dependently decreased the murine IL-6 generated by human and cynomolgus IL-1 $\alpha$ and IL-1 $\beta$ .
Animal Model:	Female C57/BL6 mice with IL-1 $\alpha$ and IL-1 $\beta$ injection <sup>[1]</sup>								
Dosage:	0.0001-1 mg/kg								
Administration:	Intraperitoneal injection, 0.0001-1 mg/kg, once								
Result:	Dose-dependently decreased the murine IL-6 generated by human and cynomolgus IL-1 $\alpha$ and IL-1 $\beta$ .								

### REFERENCES

[1]. Lacy SE, et al. Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1 $\alpha$  and IL-1 $\beta$ . MAb. 2015;7(3):605-19.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA